Validation of research site mentorship as an approach for increasing study site performance (enrollment)
4 affiliations
- 1Durham VA Health Care System, Durham, NC, USA; Corresponding author. Durham VA Health Care System, 508 Fulton Street (152), Durham, NC, 27705, USA.
- 2VA Long Beach Healthcare System, Long Beach, CA, USA
- 3Minneapolis VA Health Care System, Minneapolis, MN, USA
- 4Edward Hines, Jr. VA Hospital, Hines, IL, USA
Abstract
The identification of strategies that improve participant enrollment in clinical trials remains a key focus of stakeholders in this field, due to its role as a leading indicator of timely trial completion and its contributions to the validity and generalizability of clinical trial results. The VA Cooperative Studies Program (CSP) Network of Dedicated Enrollment Sites (NODES) replicated a previously piloted research site mentorship model in two actively enrolling CSP-funded clinical trials to validate its impact on study participant enrollment (CSP #2005: VA Lung Cancer Surgery vs. Stereotactic Radiotherapy trial (VALOR) and CSP #2008: Pentoxifylline in Diabetic Kidney Disease (VA PTXRx)). The “Total Randomized Participants (#) by Mentee Site” and the “Percentage of Randomized Participants (Actual/Expected) Monthly Average By Site (%)” were evaluated across participating mentee study sites over three time periods: 1) 5-month pre-intervention period (PIP), 2) 5-month intervention period (IP), and 3) 3-month follow-up period (FUP). These data were averaged across months during the respective time periods (PIP, IP, FUP). Our findings demonstrate an association between the NODES site mentorship model and improvements in most mentee sites' “Total Randomized Participants (#)” (4/7; 57%) at the end of the 5-month intervention period (IP), as compared to the 5-month pre-intervention period (PIP) (Table B). Increases in most sites’ (5/7; 71%) “Percentage of Randomized Participants (Actual/Expected) Monthly (Average) By Site (%)” at the end of the 5-month intervention period (IP), as compared to the 5-month pre-intervention period (PIP) was also observed (Table C).
Related
- Education Research: Career, Research, and Mentorship Outcomes of an International Neuroimmunology Education Exchange Program
- Supporting high-quality enrollment decision-making in clinical research: development of a novel informed consent communication framework and curriculum.
- Health prevention research in France: Increasing investment is a priority, rethinking targets is equally crucial
- Mentorship in hematology: A multigenerational perspective on its role in shaping the future of the field.
- Machine learning models for identifying prediabetes: a systematic review of performance, validation, and implications for primary care
BibTeX
@article{johnson2026validation,
title = {{Validation of research site mentorship as an approach for increasing study site performance (enrollment)}},
author = {Marcus R. Johnson and Aliya Asghar Uddin and Debra K. Johnson and Bin Xing and Matthew Leiner and Hua Feng and Douglas Lammie and Tom Sindowski and Cheryl Odle and Kimberly Carlson},
journal = {Contemporary Clinical Trials Communications},
year = {2026},
month = nov,
doi = {10.1016/j.conctc.2026.101703},
url = {https://doi.org/10.1016/j.conctc.2026.101703},
note = {CC BY},
}
RIS
TY - JOUR
TI - Validation of research site mentorship as an approach for increasing study site performance (enrollment)
AU - Marcus R. Johnson
AU - Aliya Asghar Uddin
AU - Debra K. Johnson
AU - Bin Xing
AU - Matthew Leiner
AU - Hua Feng
AU - Douglas Lammie
AU - Tom Sindowski
AU - Cheryl Odle
AU - Kimberly Carlson
PY - 2026
DA - 2026/11/01
JO - Contemporary Clinical Trials Communications
DO - 10.1016/j.conctc.2026.101703
UR - https://doi.org/10.1016/j.conctc.2026.101703
AB - The identification of strategies that improve participant enrollment in clinical trials remains a key focus of stakeholders in this field, due to its role as a leading indicator of timely trial completion and its contributions to the validity and generalizability of clinical trial results. The VA Cooperative Studies Program (CSP) Network of Dedicated Enrollment Sites (NODES) replicated a previously piloted research site mentorship model in two actively enrolling CSP-funded clinical trials to validate its impact on study participant enrollment (CSP #2005: VA Lung Cancer Surgery vs. Stereotactic Radiotherapy trial (VALOR) and CSP #2008: Pentoxifylline in Diabetic Kidney Disease (VA PTXRx)). The “Total Randomized Participants (#) by Mentee Site” and the “Percentage of Randomized Participants (Actual/Expected) Monthly Average By Site (%)” were evaluated across participating mentee study sites over three time periods: 1) 5-month pre-intervention period (PIP), 2) 5-month intervention period (IP), and 3) 3-month follow-up period (FUP). These data were averaged across months during the respective time periods (PIP, IP, FUP). Our findings demonstrate an association between the NODES site mentorship model and improvements in most mentee sites' “Total Randomized Participants (#)” (4/7; 57%) at the end of the 5-month intervention period (IP), as compared to the 5-month pre-intervention period (PIP) (Table B). Increases in most sites’ (5/7; 71%) “Percentage of Randomized Participants (Actual/Expected) Monthly (Average) By Site (%)” at the end of the 5-month intervention period (IP), as compared to the 5-month pre-intervention period (PIP) was also observed (Table C).
SN - 2451-8654
ER -